期刊
THERANOSTICS
卷 11, 期 16, 页码 8057-8075出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno.59677
关键词
Immunotherapy; circulating tumor cells; immune checkpoint inhibitors; cancer; personalized medicine
资金
- Ministry of Education and Science of the Russian Federation [075-15-2019-192]
- Russian Foundation for Basic Research [19-34-60034]
Immunotherapy, particularly immune checkpoint inhibitor therapy, has revolutionized cancer treatment in recent years. However, slow uptake in clinical oncology is attributed to high treatment costs, associated toxicities, and variability in patient response. Personalized approaches based on predictive biomarkers have emerged as new tools to enhance the effectiveness of immunotherapy.
Over the last few years, immunotherapy, in particular, immune checkpoint inhibitor therapy, has revolutionized the treatment of several types of cancer. At the same time, the uptake in clinical oncology has been slow owing to the high cost of treatment, associated toxicity profiles and variability of the response to treatment between patients. In response, personalized approaches based on predictive biomarkers have emerged as new tools for patient stratification to achieve effective immunotherapy. Recently, the enumeration and molecular analysis of circulating tumor cells (CTCs) have been highlighted as prognostic biomarkers for the management of cancer patients during chemotherapy and for targeted therapy in a personalized manner. The expression of immune checkpoints on CTCs has been reported in a number of solid tumor types and has provided new insight into cancer immunotherapy management. In this review, we discuss recent advances in the identification of immune checkpoints using CTCs and shed light on the potential applications of CTCs towards the identification of predictive biomarkers for immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据